Munzone, Elisabetta
Bagnardi, Vincenzo
Campennì, Giuseppe
Mazzocco, Ketti
Pagan, Eleonora
Tramacere, Andrea
Masiero, Marianna
Iorfida, Monica
Mazza, Manuelita
Montagna, Emilia
Cancello, Giuseppe
Bianco, Nadia
Palazzo, Antonella
Cardillo, Anna
Dellapasqua, Silvia
Sangalli, Claudia
Pettini, Greta
Pravettoni, Gabriella
Colleoni, Marco
Veronesi, Paolo
Funding for this research was provided by:
Fondazione Umberto Veronesi (NA)
Article History
Received: 10 January 2019
Accepted: 20 June 2019
First Online: 15 July 2019
Competing interests
: E.M. has received honorarium as consultant/advisory role from PierreFabre, Genomic Health. M.C. has received honorarium as consultant/advisory role from Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, Celldex, AstraZeneca, Novartis. E.M. has received honorarium as consultant/advisory role from PierreFabre. The remaining authors declare no competing interests.
: The study was approved by the local ethic committee (Istituto Europeo di Oncologia, IRCCS). All patients signed written informed consent. The study was performed in accordance with the Declaration of Helsinki.
: The study was funded partially by Fondazione Umberto Veronesi, and Fondazione IEO. The funding bodies had no specific role in the design of the study, collection, analysis, interpretation of data and in writing the manuscript.
: Data supporting the results reported in the article are available at Clinical Trial Office, European Institute of Oncology, Milan, Italy. Restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of European Institute of Oncology, Milan, Italy.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).